Rapid semiquantitative real-time PCR for the detection of human cytomegalovirus UL97 mutations conferring ganciclovir resistance

Antiviral Therapy

Volumn 13, Issue 3, 2008, Pages 461-466

  Göhring, Katharina ^a   Mikeler, Elfriede ^a   Jahn, Gerhard ^a   Rohde, Frank ^b   Hamprecht, Klaus ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; ANTIVIRUS AGENT; GANCICLOVIR KINASE; PHOSPHOTRANSFERASE;

ANTIVIRAL RESISTANCE; ARTICLE; CODON; COMPARATIVE STUDY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; HYBRIDIZATION; LABORATORY; MELTING POINT; PLASMID; POINT MUTATION; POPULATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; TIME; UL97 GENE; VIRUS DETECTION; VIRUS GENE; VIRUS MUTANT; VIRUS MUTATION; VIRUS STRAIN; WILD TYPE; CYTOMEGALOVIRUS; DRUG EFFECT; ENZYMOLOGY; GENETICS; GENOTYPE; METHODOLOGY; MUTATION; PHENOTYPE; POLYMERASE CHAIN REACTION; REPRODUCIBILITY;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; DRUG RESISTANCE, VIRAL; GANCICLOVIR; GENOTYPE; HUMANS; MUTATION; PHENOTYPE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 47249086917     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Baldanti F, Lurain N, Gerna G. Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. Hum Immunol 2004; 65:403-409.
2. Limaye AP. Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients. Sem Respir Infect 2002; 17:265-273.
3. Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanism. Drug Res Update 2002; 5:88-114.
4. Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005; 49:873-883.
5. Chou S. Antiviral drug resistance in human cytomegalovirus. Transpl Infect Dis 1999; 1:105-114.
6. Erice A. Resistance of human cytomegalovirus to antiviral drugs. Clin Microbiol Rev 1999; 12:268-297.
7. Baldanti F, Underwood MR, Talarico CL, et al. The Cys 607?Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients. Antimicrob Agents Chemother 1998; 42:444-446.
8. Hamprecht K, Eckle T, Prix L, Faul C, Einsele H, Jahn G. Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of UL97 mutant strain. J Infect Dis 2003; 187:139-143.
9. Göhring K, Mikeler E, Jahn G, Hamprecht K. Rapid simultaneous detection of cytomegalovirus UL97 mutations in codon 460 and 520 conferring ganciclovir resistance by real time PCR. J Clin Microbiol 2006; 44:4541-4544.
10. Eckle T, Jahn G, Hamprecht K. High impact of an expanded restriction fragment length polymorphism assay on detection of ganciclovir-resistant UL97 mutants of human cytomegalovirus. Antimicrob Agents Chemother 2003; 47:442-443
11. Hanson, MN, Preheim LC, Chou S, Talarico CL, Biron KK, Erice A. Novel mutation in UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir. Antimicrob Agents Chemother 1995; 39:1204-1205.
12. Chou S, Erice A, Jordan MC, et al. Analysis of UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J Infect Dis 1995; 171:576-583.
13. Prix L, Hamprecht K, Holzhüter B, Hangretinger R, Klingebiel T, Jahn G. Comprehensive restriction analysis of UL97 region allows early detection of ganciclovir-resistant human cytomegalovirus in an immunocompromised child. J Infect Dis 1999; 180: 491-495.
14. Eckle T, Jahn G, Hamprecht K. The influence of mixed HCMV UL97 wildtype and mutant strains on ganciclovir susceptibility in a cell associated plaque reduction assay. J Clin Virol 2003; 30:50-56.
15. Hantz S, Michel D, Fillet AM, et al. Early selection of a new UL97 mutant with a severe defect of ganciclovir phosphorylation after valaciclovir prophylaxis and short-term ganciclovir therapy in a renal transplant recipient. Antimicrob Agents Chemother 2005; 49:1580-1583.
16. Marfori JE, Exner MM, Marousek GI, Chou S, Drew WL. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. J Clin Virol 2007; 38:120-125.